Treatment of Psoriasis with Interleukin-10 Kristian Reich, Andrea Gräfe, Claudia Vente, Christine Neumann  Journal of Investigative Dermatology  Volume 111, Issue 6, Pages 1235-1236 (December 1998) DOI: 10.1046/j.1523-1747.1998.00444.x Copyright © 1998 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 1 Systemic administration of IL-10 reduces the clinical activity of psoriasis. Reduction of the PASI after 3 and 6 wk in 10 patients with moderate-to-severe psoriasis injected daily for 42 d with 4 μg per kg body weight of subcutaneous rhIL-10. The patient number is followed by the gender (f, female; m, male), the age (y), and the duration of psoriasis (y). *In patient 1, treatment was stopped after 5 wk because of a newly diagnosed immunogenic hyperthyroidism. Journal of Investigative Dermatology 1998 111, 1235-1236DOI: (10.1046/j.1523-1747.1998.00444.x) Copyright © 1998 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 2 IL-10 controls epidermal hyperplasia and inflammatory infiltration in psoriasis. Example of sonographic (a, b) and histologic (c, d) improvement of the same marker lesion after treatment with IL-10 (patient 8). Journal of Investigative Dermatology 1998 111, 1235-1236DOI: (10.1046/j.1523-1747.1998.00444.x) Copyright © 1998 The Society for Investigative Dermatology, Inc Terms and Conditions